- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05510505
GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT
A Prospective, Randomized, Multi-center Study to Assess the Efficacy and Safety of GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in Severe Aplastic Anemia Patients With Treatment of Allogeneic HSCT
Objectives 2.1 Primary objectives
1) To observe and compare incidence and severity of aGVHD and cGVHD between the two arms within 2 years after transplantation.
2) To observe and compare the engraftment rate between the two arms. 3) To observe and compare the incidence of infections between the two arms. 2.2 Secondary objectives
- To conduct pharmacogenomic assay in CD20 arm(treatment arm) before conditioning and monitor plasma concentration of CD20 dynamically(7d、14d、28d、56d、91d).
- To monitor levels of B cells in peripheral blood dynamically (+90d、+180d、+270d、+360d、+450d、+540d、+630d、+720d) in all patients.
- To observe and compare the incidence of PTLD between the two arms.
- To observe and compare immunoglobulin levels after transplantation in all patients.
- To evaluate transplant-related mortality.
- To evaluate the effect on hematopoietic reconstruction.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
3. Study design 3.1 Principle of design: prospective, randomized, control, open label 3.2 Subjects: patients with SAA undergoing allogeneic HSCT 3.3 Grouping: In this study, central randomization was used for random enrolment (1:1). After signing the informed consent, patients were randomized into rituximab conditioning group (test group) or non- rituximab conditioning group (control group). Treatment was assigned on a randomized basis according to a 1:1 ratio. The test group and the control group each will include 100 cases.
3.4 Study schedule: This clinical research is to be completed from September 2020 to September 2023.
- Subject enrollment 36months
- Transplantation to the end of follow-up 24months
- Data collection and report writing 3months In total 63months
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: depei wu
- Phone Number: 0512 67781856
- Email: wudepei@suda.edu.cn
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215215
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Contact:
- depei wu
- Phone Number: 0512 67781856
- Email: wudepei@suda.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects eligible for inclusion in this study must meet all of the following criteria:
- SAA characterized Bone marrow cellularity< 25%, or 25-50% with <30% residual hematopoietic cells and pancytopenia, with at least two of the following parameters in peripheral blood Absolute neutrophil count < 0.5*10E9/L Platelet count < 20*10E9/L Absolute reticulocyte count < 20*10E9/L
- ALL patients will undergo allo-HSCT.
- Subjects aged <50 years old with KPS performance status ≥70 at the same time.
- Aspartate aminotransferase (AST) , alanine aminotransferase (ALT) and alkaline phosphatase≤2 times the upper limit of normal (ULN). Blood urea nitrogen and Creatinine ≤1.25 times ULN.
- Cardiac function of subjects must meet all of the following requirements: ECG examination do not reveal any acute myocardial infarction, arrhythmia, or first-degree or higher atrioventricular block. No signs of heart failure. No carrying of active rheumatoid heart disease. Chest radiograph or physical examination do not indicate an enlarged heart.
- ALL subjects show none contraindication for allogeneic hematopoietic stem cell transplantation.
- Patients enrolled in the rituximab group have no contraindications for the use of rituximab.
- Patients and their clients are willing to perform hematopoietic stem cell transplantation.
- Potential donor is accessible.
- Patients have no anti-HLA antibodies.
Exclusion Criteria:
- Subject who is unable comprehend or is unwilling to sign an informed consent form or consent form due to severe physical or mental illness resulting in a survival of less than 2 years.
- Presence of clinically active uncontrolled significant chronic infections (including bacterial, fungal or viral infection), such as dental caries, otitis media, sinusitis, etc., need to be carried out after effective control.
- Past medical history of severe pulmonary dysfunction.
- Past medical history of diabetes with a propensity for ketoacidosis.
- Presence of severe coagulopathy, thrombophlebitis or pulmonary embolism.
- Presence of decompensated liver insufficiency or active hepatitis.
- Presence of history of severe autoimmune disease.
- Past medical history of thyroid dysfunction with currently abnormal thyroid function.
- Any concomitant malignancies that have not been disease-free for 5 years.
- Past medical history of hypersensitivity to biological products (including antibiotics).
- Pregnant or nursing woman.
- Inherited bone marrow failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ATG arm (control group)
4.2.1 Matched sibling donor 1) ATG arm (control group) Fludarabine 30mg/m2/d×6d(-7d ~ -2d)+ Cyclophosphamide 50mg/kg/d×2d (-4d ~ -3d)+ ATG 2.5mg/kg/d×5d(-8d ~ -4d) 4.2.2 Unrelated donor and haploidentical donor 1) ATG arm (control group) Busulfan 3.2 mg/kg/d(0.8 mg/kg,q6h)×2d(-7d ~ -6d) + Cyclophosphamide 50mg/kg/d×4d (-5d ~ -2d)+ ATG 2.5mg/kg/d×4d(-5d ~ -2d) |
4.2 Conditioning Regimen 4.2.1 Matched sibling donor
4.2.2 Unrelated donor and haploidentical donor
|
Experimental: ATG + CD20 monoclonal antibody (test arm)
4.2.1 Matched sibling donor 2) ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d(-7d ~ -2d) + Cyclophosphamide 50mg/kg/d×2d (-4d ~ -3d)+ ATG 2.5mg/kg/d×5d(-8d ~ -4d)+ CD20 monoclonal antibody 375mg/m2, -1d 4.2.2 Unrelated donor and haploidentical donor 2) ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d(0.8 mg/kg,q6h)×2d(-7d ~ -6d) + Cyclophosphamide 50mg/kg/d×4d (-5d ~ -2d)+ ATG 2.5mg/kg/d×4d(-5d ~ -2d)+ CD20 monoclonal antibody 375mg/m2, -1d |
4.2 Conditioning Regimen 4.2.1 Matched sibling donor
4.2.2 Unrelated donor and haploidentical donor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GVHD incidence
Time Frame: 2 years
|
GVHD incidence, location and grade.
Infection incidence and recurrence rate.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infection incidence
Time Frame: 2 years
|
Cumulative incidence of infection post-transplant
|
2 years
|
GVHD-free survival rate
Time Frame: 2 years
|
defined by the percentage of patients who are alive without evidence of moderate or severe chronic GVHD at 2 year
|
2 years
|
transplant related mortality
Time Frame: 2 years
|
Defined as the number of days from the date of transplant to the date of death related to transplant
|
2 years
|
overall survival rate
Time Frame: 2 years
|
OS is defined as the number of days from the date of transplant to the date of death
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Depei Wu, The First Affiliated Hospital of Soochow University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAA-HSCT-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aplastic Anemia
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
University of UtahNovartisCompletedSevere Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic AnemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Severe Aplastic Anemia | Refractory Severe Aplastic AnemiaUnited States
-
Peking University People's HospitalRecruiting
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingSevere Aplastic AnemiaUnited States
-
Federal Research Institute of Pediatric Hematology...RecruitingAcquired Aplastic AnemiaRussian Federation
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaboratorsCompleted
-
Nagoya UniversityUnknownAcquired Aplastic Anemia.Japan
-
Navy General Hospital, BeijingPeking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaboratorsUnknownSevere Aplastic AnemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
Clinical Trials on ATG
-
Antengene CorporationTerminatedRelapsed/Refractory Diffuse Large B-cell LymphomaChina
-
IRCCS Burlo GarofoloCompletedHematopoietic Stem Cell TransplantationItaly
-
Qi ZhouNot yet recruiting1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerChina
-
Antengene (Hangzhou) Biologics Co., Ltd.RecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin LymphomaChina
-
Antengene Biologics LimitedRecruitingAdvanced Solid Tumors | B-cell Non-Hodgkin LymphomasUnited States
-
Antengene Biologics LimitedRecruitingAdvanced/Metastatic Solid TumorsChina, Australia
-
Shanghai Antengene Corporation LimitedTerminated
-
Antengene Therapeutics LimitedTerminatedHepatocellular CarcinomaKorea, Republic of, Taiwan, China
-
Antengene Discovery LimitedRecruitingAdvanced Solid Tumors | Hematological MalignanciesAustralia
-
Shanghai Antengene Corporation LimitedTerminated